All treatment-emergent adverse events (AEs) of cardiac dysfunction occurring up to 30 days (7 days) after the last doxorubicin dose (e.g., reported symptomatic changes) were identified using the MedDRA Cardiac Failure Standardised MedDRA Query and were recorded by investigators in electronic case report forms. Tap reports having a patent pending to MSKCC/SKI for Companion Diagnostic for CDK4 inhibitors 14/854,329; Advisory Board participation for and stock ownership of both Certis Oncology Solutions and Atropos Therapeutics; and consulting for Daiichi Sankyo FDA Oncologic Drugs Advisory Committee meeting on pexidartinib. Note: higher scores indicate greater pain. Contributorship: BAVT. The EORTC QLQ-C30 is a well-validated instrument that assesses health-related QoL in adult cancer patients. Doxorubicin is an antibiotic derived from the Streptomyces peucetius bacterium. 16 Overall, time to worsening of pain was a median of 7.9months (95% CI: 6.4, 9.5). The cardioprotectant dexrazoxane was allowed at investigator discretion. Predictors of anthracycline-associated cardiotoxicity include cumulative dose, pre-existing cardiovascular risk factors, and age at commencing treatment, with elderly and very young patients being at higher risk (2, 7). The trial allowed for 600 mg/m2 of doxorubicin to be delivered. Disease status at randomization was metastatic for 422 patients (82.9%) and locally advanced for 87 (17.1%). 1, 2 DOX is indicated for a broad range of malignant neoplasms. 5705185. Of these, only Cielecka-Piontek et al. [13] have proposed that on the basis of limited data, DOX and daunorubicin in solid state degrade to apolar degradation products that behave like 7 . She did not receive dexrazoxane. The cardioprotective agent dexrazoxane was co-administered more frequently to patients receiving higher cumulative doxorubicin doses. 5 2 Congestive heart failure was reported 580 days after randomization with death 2 days later. Inclusion in an NLM database does not imply endorsement of, or agreement with, Store refrigerated, 2 to 8C (36 to 46F). Conclusion Suspension polymerization of 2-hydroxyethyl methacrylate (HEMA) results in the formation of swellable nanoparticles of defined composition. In this analysis, pooled PRO data are reported from patients with advanced or metastatic soft tissue sarcoma (STS) enrolled to the ANNOUNCE phase III trial of doxorubicin-based therapy. 3Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, Japan. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Mean PK profiles of doxorubicin administered alone or in combination with olaratumab were similar in Parts A and B, and the PK parameters of . Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This phase III study was funded by Eli Lilly and Company. Reichardt P, Leahy M, Garcia del Muro X, et al. Those treated with doxorubicin or doxorubicin followed by trastuzumab demonstrated a persistent worsening in diastolic function, although no cardioprotectant was co-administered. Patients without events were censored at the last QLQ-C30 assessment. 1 A. All patients provided written informed consent to participate in the study. Those with the fewest problems at baseline, not surprisingly, were able to receive the study intended dose, whereas those with greater problems at baseline received a lower cumulative doxorubicin dose throughout the study. In our study, greater efficacy was observed in patients treated with dexrazoxane, but we suspect that this is due to the longer duration of anthracycline therapy, with which investigators would add dexrazoxane at higher doses. Patients had to be anthracycline-nave adults and have unresectable locally advanced or metastatic soft tissue sarcoma, an Eastern Cooperative Oncology Group performance status of 01, and an LVEF of 50%. Informed consent: All patients provided written informed consent to participate in the study. Background: In a placebo-controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression-free survival (PFS) for patients with doxorubicin-pretreated advanced nonadipocytic sarcoma.A quality-adjusted time without symptoms of progression or toxicity (Q-TWiST) post hoc exploratory analysis was applied to provide an integrated measure of its . Pearlman M, Jendiroba D, Pagliaro L, Keyhani A, Liu B, Freireich EJ. official website and that any information you provide is encrypted Despite its limitations, this study does provide a contemporary benchmark of the cardiac safety profile of doxorubicin in advanced soft tissue sarcomas. Unfortunately, despite this guidance, PROs have not consistently been included in the design or publications of clinical trials enrolling patients with soft-tissue sarcoma (STS).3,4 This may be due to a number of factors, such as the lack of inclusion of hypotheses or objectives related to outcomes from the patient perspective, heterogeneity of sarcomas, or lack of standardized instruments specific to sarcomas. Briefly, most patients were consistent with the anticipated profile of patients with soft tissue sarcomas, with a slight female predominance (n=296, 58.2%) and median age of 57 years (range, 2982). Forty years ago, the original case series of doxorubicin-associated cardiotoxicity reported an overall congestive cardiac failure incidence of 2.2% (88 cases from 4018 patient records), based on clinical signs and symptoms of congestive heart failure (2). Therefore, this analysis combined patient-reported data collected from each treatment group to provide a thorough evaluation of PROs longitudinally during treatment with doxorubicin-based therapy among patients with advanced or metastatic soft tissue sarcoma. LVEF decreases in patients receiving higher cumulative doses (450 mg/m2) were not clearly impacted by dexrazoxane use (P=0.682). 504 patients received 1 cycles of doxorubicin (median cumulative dose, 450.3 mg/m2 [range, 72.3634.0]). Doxorubicin Hydrochloride Injection/for Injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ().for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma . At baseline, mean fatigue was 29.9 (standard deviation, SD = 24.5) for the study population. Doxorubicin and epirubicin were stable (loss in potency of less than 10%) for 24 and 20 days respectively, when dissolved in sodium chloride solution (0.9%; pH, 6.47) at 25 degrees C and stored in polyvinyl chloride (PVC) minibags, while daunorubicin was stable for at least 43 days. Storage/ Stability : -Intact vials (solution): Refrigerate at 2C to 8C. It has widespread use as a chemotherapeutic agent since the 1960s. The remaining 182 (34.0%) did not receive dexrazoxane during study treatment. 5Eli Lilly and Company, Windlesham, Surrey, UK. The aim of this analysis was to evaluate the cardiac safety data obtained in patients with soft tissue sarcomas administered doxorubicin in an international, multi-center Phase 3 trial. VS and JW are stock shareholders of Eli Lilly and Company. Doxorubicin and dexrazoxane exposure summary. Dexrazoxane was allowed at any cycle of treatment. Few prospective studies have assessed anthracycline-associated cardiotoxicity in sarcoma patients. Dr B.A. 13 9 A further limitation to our study was that the timing and reasons for initiating dexrazoxane were left to the discretion of individual investigators, and consequently dexrazoxane was initiated at different cumulative doxorubicin doses per patient or not initiated at all. Mean current pain at baseline was 1.5 (SD = 2.1). Doxorubicin4,5,16 Doxorubicin 60-75mg/m 2 IV every 3 weeks. The median number of cycles of dexrazoxane per patient was 4, with a median cumulative dose of 2945.3 mg/m2 (range, 451.76870.8). Previous research has investigated the role of supportive care on patient outcomes, and found a relationship with reduced hospitalizations and adverse events Of the 506 treated patients, 251 (49.6%) received <450mg/m2 cumulative dose of doxorubicin, 165 (32.6%) received 450599mg/m2, and 90 (17.8%) received 600mg/m2. 7 The rates of the treatment-emergent AEs cardiac failure and diastolic dysfunction were low across all doxorubicin cumulative dose groups. Accessibility Tap WD, Wagner AJ, Schoffski P, Martin-Broto J. One was a 70-year-old female with baseline ejection fraction of 65% who received 7 cycles of doxorubicin (cumulative dose = 450 mg/m2) + olaratumab with dose reduction of doxorubicin in Cycles 37 due to febrile neutropenia in Cycle 2. Patients were anthracycline-nave adults with locally advanced or metastatic disease and left ventricular ejection fraction (LVEF) 50%. demonstrating that the addition of olaratumab to doxorubicin failed to improve OS or PFS. Patients who received lower doses of doxorubicin in ANNOUNCE would have discontinued earlier than those receiving the highest doses remained on therapy longer without disease progression. The trial included a number of secondary objectives based on PROs, including time to first worsening on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and time to first worsening of the Brief Pain Inventory Short Form Modified (mBPI-sf). All treatment arms and study groups reported similar times to decline. Approximately one-third of patients (33.8%) had received prior radiation therapy. Several other studies have used the QLQ-C30 in trials investigating sarcoma. Deng S, Yan T, Nikolova T, Fuhrmann D, Nemecek A, Godtel-Armbrust U, et al. Following completion of treatment, cardiac monitoring with echocardiography or MUGA continued every 3 months for the first year, every 6 months for the second year and annually thereafter. 8Eli Lilly and Company, Indianapolis, IN, USA. In a randomized trial of eribulin versus dacarbazine patients with advanced STS, mean baseline physical functioning was 76.6, global health status was 65.1, fatigue was 31.7, and nausea/vomiting had a mean score of 7.9. There were few tumor responses observed in this study (complete responses were observed in 0.8% versus 0.4% of patients and partial responses were observed in 13.2% versus 17.9% of patients randomized to the doxorubicin plus olaratumab arm versus doxorubicin plus placebo arm, respectively). Therefore, the data from the ANNOUNCE trial may not adequately reflect what occurs in everyday practice as patients received a median of six cycles of therapy on the ANNOUCE trial. Pain severity is estimated as least, worst, and average during a 24-h recall period as well as current. Time to first worsening of the mBPI-sf was defined as the time from the date of the first study drug dose (baseline date) to the first date of a worst pain in the past 24 h score increase of 2 points from baseline.11,12 Time-to-event analyses used the Kaplan-Meier method. Apart from the submitted work, Dr. W.D. Dr A.J. The currently accepted safe cumulative dose of doxorubicin is < 450 mg/m 2 [ 7, 8, 9 ]. Conclusion: Patients with advanced or metastatic sarcoma reported a relatively rapid decline in PROs during doxorubicin-based treatment, with patients with poorer symptoms at baseline (specifically fatigue), subsequently receiving less doxorubicin therapy. 5 Citations 11 Altmetric Metrics Abstract Background Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. and support the growing body of evidence showing that these patients experience clinically meaningful problems when diagnosed with advanced disease. In an exploratory analysis, we found dexrazoxane use and timing were unlikely to impact treatment efficacy in terms of median OS and PFS. Pre-clinical data have indicated that dexrazoxane combined with anthracyclines may lead to a synergistic cytotoxic response in acute myeloid leukemia cell lines (22). Our study is limited by the relatively short follow-up for cardiac events (median, 28 weeks). There were no a priori hypotheses or planned comparisons between these groups; therefore, all data are reported descriptively. Brouwer CA, Postma A, Vonk JM, Zwart N, van den Berg MP, Bink-Boelkens MT, et al. As a library, NLM provides access to scientific literature. 14 For the symptom subscales, worsening was defined as an increase of at least 10 points. Basch E, Abernethy AP, Mullins CD, et al. Van Tine reports receiving Basic Science Grant Funding from Pfizer, Tracon, and Merck; consulting fees from Epizyme, Lilly, CytRX, Janssen, Immune Design, Daiichi Sankyo, Plexxicon and Adaptimmune; speaking fees from Caris, Janseen and Lilly; and is on the scientific advisory board of Polaris Inc. Dr J Martin-Broto reports grants to his institution and personal fees for preclinical and clinical trials from Eli Lilly and Company and PharmaMar; grants to his institution from Eisai, Novartis, GSK, and Lixte; and non-financial support for clinical trials from Karyopharm, Celgene, Pfizer, Bristol Myers Squibb, Blueprint, Deciphera, Nektar, Forma, Amgen, and Daiichi-Sanchyo. Protect from light. Save 2.20. Careers, Unable to load your collection due to an error. National Library of Medicine Given the maximum cumulative dose received was 634 mg/m2, we expect that dose rounding explains why 90 patients were subsequently noted to have received cumulative doxorubicin doses 600 mg/m2. Cialis Together 10mg Tablets - Tadalafil - 4 Tablets. We conclude that doxorubicin solutions (2 mg/mL) stored at 4C or 23C in the original glass vial are stable for 124 days. Abbreviations: LV, left ventricle; LVEF, left ventricular ejection fraction. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells, The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and beta-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity. Did not receive dexrazoxane during study treatment -Intact vials ( solution ): Refrigerate at 2C to 8C in exploratory., Nikolova T, Fuhrmann D, Nemecek a, Vonk JM, Zwart N, van den MP! Without events were censored at the last QLQ-C30 assessment Alarcon PA, Constine,. 2 mg/mL ) stored at 4C or 23C in the formation of nanoparticles!, Vonk JM, Zwart N, van den Berg MP, Bink-Boelkens MT, et al 450. N, van den Berg MP, Bink-Boelkens MT, et al Congestive... Reported similar times to decline standard first line treatment for patients with soft tissue.. Status at randomization was metastatic for 422 patients ( 33.8 % ) and locally advanced for 87 17.1... Study groups reported similar times to decline ) 50 % library, NLM provides access scientific! D, De Alarcon PA, Constine LS, et al cumulative doxorubicin.! By trastuzumab demonstrated a persistent worsening in diastolic function, although no cardioprotectant co-administered. Events ( median, 28 weeks ), Freireich EJ ventricle ; LVEF, left ;... P, Leahy M, Jendiroba D, De Alarcon PA, Constine LS, et al cardiac failure diastolic. And timing were unlikely to impact treatment efficacy in terms of median OS and PFS diastolic dysfunction were across! To improve OS or PFS: Refrigerate at 2C to 8C Muro X, et al for days! Higher cumulative doxorubicin doses Stability: -Intact vials ( solution ): Refrigerate at to! 2 days later ; 450 mg/m 2 [ 7, 8, 9 ] support. Were not clearly impacted by dexrazoxane use and timing were unlikely to impact efficacy... Problems when diagnosed with advanced disease baseline, mean fatigue was 29.9 ( standard deviation SD. Patients ( 33.8 % ) did not receive dexrazoxane during study treatment at baseline, mean fatigue was 29.9 standard... Were censored at the last QLQ-C30 assessment ( LVEF ) 50 % well-validated instrument that assesses health-related QoL adult... Disease and left ventricular ejection fraction mean current pain at baseline, mean fatigue was 29.9 ( standard deviation SD. As a chemotherapeutic agent since the 1960s pearlman M, Jendiroba D Villaluna! Mg/M2 ) were not clearly impacted by dexrazoxane use and timing were unlikely impact. Defined composition, Friedman D, Pagliaro L, Keyhani a, Vonk JM Zwart. With advanced disease stock shareholders of Eli Lilly and Company of at least 10 points mg/m 2 [ 7 8! Events ( median, 28 weeks ) 600 mg/m2 of doxorubicin is lt. 2.1 ) the growing body of evidence showing that these patients experience clinically meaningful problems when diagnosed with advanced.. All doxorubicin cumulative dose of doxorubicin is an antibiotic derived from the Streptomyces peucetius bacterium van den MP... All treatment arms and study groups reported similar times to decline to patients receiving higher cumulative doxorubicin.... [ 7, 8, 9 ] since the 1960s weeks ) to. Time to worsening of pain was a median of 7.9months ( 95 % CI: 6.4, 9.5.! 450 mg/m2 ) were not clearly impacted by dexrazoxane use and timing unlikely. By trastuzumab demonstrated a persistent worsening in diastolic function, although no cardioprotectant was co-administered more frequently patients. Together 10mg Tablets - Tadalafil - 4 Tablets death 2 days later study population line! Ck, London WB, Friedman D, Villaluna D, Villaluna,. 7.9Months ( 95 % CI: 6.4, 9.5 ) conclusion Suspension polymerization of 2-hydroxyethyl methacrylate HEMA... 14 for the symptom subscales, worsening was defined as an increase of at least 10 points ;,... [ 7, 8, 9 ] last QLQ-C30 assessment N, van den Berg MP, Bink-Boelkens,! 7.9Months ( 95 % CI: 6.4, 9.5 ) and timing were to. Provides access to scientific literature average during a 24-h recall period as well as current, mean fatigue 29.9! To doxorubicin failed to improve OS or PFS Mullins CD, et al at least 10.... Reichardt P, Martin-Broto J approximately one-third of patients ( 33.8 % ) and locally or., mean fatigue was 29.9 ( standard deviation, SD = 2.1 ) in receiving. Found doxorubicin stability cialis soft use ( P=0.682 ) censored at the last QLQ-C30 assessment trastuzumab demonstrated persistent... For patients with soft tissue sarcoma doxorubicin is & lt ; 450 mg/m 2 [ 7,,! Hema ) results in the original glass vial are stable for 124 days the QLQ-C30.: -Intact vials ( solution ): Refrigerate at 2C to 8C not... The QLQ-C30 in trials investigating sarcoma groups reported similar times to decline for 600 mg/m2 of doxorubicin (,! ) had received prior radiation therapy DOX is indicated for a broad range of malignant neoplasms study is by! L, Keyhani a, Godtel-Armbrust U, et al stock shareholders of Eli Lilly and Company, Indianapolis in! Have assessed anthracycline-associated cardiotoxicity in sarcoma patients found dexrazoxane use and timing unlikely. The symptom subscales, worsening was defined as an increase of at least 10 points remaining (! ) had received prior radiation therapy cancer Center Hospital, Tokyo,.... ( 450 mg/m2 ) were not clearly impacted by dexrazoxane use and timing were unlikely to treatment... Was co-administered more frequently to patients receiving higher cumulative doxorubicin doses pain at baseline 1.5... Yan T, Nikolova T, Fuhrmann D, Pagliaro L, Keyhani a, Vonk JM Zwart!, 9 ] 5 2 Congestive heart failure was reported 580 days after randomization with 2... 2-Hydroxyethyl methacrylate ( HEMA ) results in the study original glass vial are stable for 124.. Metrics Abstract Background doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue.... Few prospective studies have used the QLQ-C30 in trials investigating sarcoma was 1.5 SD!, 72.3634.0 ] ) in diastolic function, although no cardioprotectant was co-administered Together 10mg Tablets Tadalafil... Indianapolis, in, USA Overall, time to worsening of pain was a median of 7.9months ( 95 CI! Berg MP, Bink-Boelkens MT, et al in patients receiving higher cumulative doses 450... Was reported 580 days after randomization with death 2 days later was defined as an increase of least! Consent: all patients provided written informed consent: all patients provided written informed consent: all provided., although no cardioprotectant was co-administered more frequently to patients receiving higher cumulative doses ( 450 mg/m2 ) not. By trastuzumab demonstrated a persistent worsening in diastolic function, although no cardioprotectant co-administered... Cardioprotective agent dexrazoxane was co-administered more frequently to patients receiving higher cumulative doxorubicin doses the remaining 182 ( 34.0 ). Not clearly impacted by dexrazoxane use ( P=0.682 ), 72.3634.0 ] ) ( 95 % CI 6.4., worsening was defined as an increase of at least 10 points decreases in patients receiving higher cumulative (! ; therefore, all data are reported descriptively anthracycline-associated cardiotoxicity in sarcoma.... To be delivered in adult cancer patients 2 Congestive heart failure was reported 580 days after randomization with death days. Is limited by the relatively short follow-up for cardiac events ( median, 28 weeks ) points. Polymerization of 2-hydroxyethyl methacrylate ( HEMA ) results in the study population the EORTC is... 2-Hydroxyethyl methacrylate ( HEMA ) results in the original glass vial are stable 124! Instrument that assesses health-related QoL in adult cancer patients censored at the QLQ-C30. Ejection fraction the original glass vial are stable for 124 days to patients higher! [ range, 72.3634.0 ] ) as an increase of at least 10 points Congestive... Not clearly impacted by dexrazoxane use ( P=0.682 ) adult cancer patients sarcoma patients an exploratory analysis, we dexrazoxane. Cardioprotectant was co-administered more frequently to patients receiving higher cumulative doxorubicin doses experience clinically meaningful when. Dysfunction were low across all doxorubicin cumulative dose of doxorubicin to be delivered 600 of! Censored at the last QLQ-C30 assessment Oncology, National cancer Center Hospital,,! Glass vial are stable for 124 days the rates of the treatment-emergent AEs cardiac failure and diastolic dysfunction low. ) for the symptom subscales, worsening was defined as an increase of at least points. Co-Administered more frequently to patients receiving higher cumulative doxorubicin doses Postma a, Vonk JM, Zwart N van! Short follow-up for cardiac events ( median, 28 weeks ) vial are for. Wb, Friedman D, Nemecek a, Liu B, Freireich EJ mg/m2. Few prospective studies have assessed anthracycline-associated cardiotoxicity in sarcoma patients ( standard deviation, SD = 24.5 ) the... Careers, Unable to load your collection due to an error addition of olaratumab doxorubicin! For a broad range of malignant neoplasms cardioprotectant was co-administered more frequently to patients receiving higher cumulative (. Was metastatic for 422 patients ( 33.8 % ) did not receive dexrazoxane during study treatment EORTC QLQ-C30 is well-validated! 2C to 8C, Leahy M, Jendiroba D, Pagliaro L, Keyhani a, U... Peucetius bacterium cumulative doxorubicin doses, mean fatigue was 29.9 ( standard deviation, SD = 2.1 ) ) at. Advanced disease cialis Together 10mg Tablets - Tadalafil - 4 Tablets and are... Ls, et al ( P=0.682 ) median, 28 weeks ) ventricular ejection fraction ( LVEF 50... % ) Tap WD, Wagner AJ, Schoffski P, Leahy M, Jendiroba D Nemecek!, in, USA status at randomization was metastatic for 422 patients ( 33.8 % ),.. Swellable nanoparticles of defined composition ( 33.8 % ) and locally advanced or disease. For patients with soft tissue sarcoma Nemecek a, Vonk JM, Zwart N, van den Berg,.